Clinical trial · Observational
Cerebral Prophylactic Irradiation With Saving Hippocampus and Amygdala
Savings of Hippocampus and Amygdala by Archetherapy in Cerebral Prophylactic Irradiation in Patients With Limited and / or Extended, Responsive or Stable Small Cell Lung Cancer (SCLC)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): diffciculties to recruit patients and a lot of patients prematurely terminated
Summary
Brief summary (as posted)
Hippocampus and amygdala are parts of the brain involved in the recognition of emotions, memories, memory, language ... It is therefore very important to protect them during irradiation of the brain. The aim of this study is to evaluate cerebral irradiation with saving hippocampus and amygdala protects these brain functions in patients with small cell lung cancer (SCLC) Radiotherapy of the brain
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Irradiation prophyllactique cérébrale | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Irradiation prophyllactique cérébrale
- interventionNames
- Radiation: Irradiation prophyllactique cérébrale
Primary outcomes (1)
- measure
- Cognitive function
- timeFrame
- until 18 months after inclusion of patient
- description
- Evaluate the cognitive function with Wechsler Memory Scale IV (WMS-IV) test
Secondary outcomes (3)
- measure
- Secondary effects according the CTCAE v.4 criteria
- timeFrame
- until 18 months after inclusion of patient
- description
- Evaluate the toxicity according the CTCAE v.4 criteria
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients over 18 years of age * Patients with a limited SCLC demonstrated histologically responsive or stable to radiochemotherapy or patients with a histologically proven extended SCLC responding to chemotherapy. * WHO Performance Index 0-1 and / or Karnovsky Index\> 70 * Possibility of long-term monitoring Exclusion Criteria: * Concomitant chemotherapy * Impossibility of performing an MRI or CT without injection * Presence of cerebral metastases * History of cerebral irradiation at any time * Patient suffering from severe collagenosis * Patient with cognitive disorders with MMSE score \<24
References
Publications (0)
Data not yet available